November 2024
FDA Denies Full Approval for Ocaliva in Primary Biliary Cholangitis, Accelerated Approval Stands
FDA, Ocaliva, Intercept Pharmaceuticals, primary biliary cholangitis, accelerated approval, rare liver disease
Syndax’s Revumenib Shows Promising Results in Acute Leukemia Trials, Paving Way for FDA Approval
Revumenib, Acute Leukemia, AUGMENT-101, SAVE Trial, BEAT AML, Syndax Pharmaceuticals, FDA Approval
Metsera Secures $215 Million Series B Funding Following Promising Phase 1 Weight Loss Data
Metsera, Series B funding, weight loss, obesity treatment, GLP-1 drugs, NuSH peptides
FDA Issues Second Clinical Hold on Kezar’s Zetomipzomib Program Within Two Months
Kezar Life Sciences, Zetomipzomib, FDA Clinical Hold, Lupus Nephritis, Autoimmune Hepatitis, Clinical Trials
Novartis and Schrödinger Forge $150M Drug Discovery Partnership with Billions in Potential Milestones
Novartis, Schrödinger, drug discovery pact, $150M upfront payment, multiyear collaboration, multi-target agreement.
Novartis Joins Eurovision 2025 as Official Partner
Eurovision 2025, Novartis, Official Partner, Basel, Switzerland
Neurogene’s Rett Syndrome Gene Therapy Shows Efficacy but Raises Safety Concerns
Neurogene, Rett syndrome, gene therapy, NGN-401, AAV vector, clinical trial, safety concerns, efficacy results
GSK Enters Strategic Alliance with Vesalius Therapeutics for Parkinson’s Disease Treatments
GSK, Vesalius Therapeutics, Parkinson’s disease, neurodegenerative diseases, strategic alliance, small molecule program
Pfizer Weighs Sale of Hospital Drugs Unit Amid Activist Pressure
Pfizer, hospital drugs unit, sale, activist investor, Starboard Value, Goldman Sachs
Roche and Flare Therapeutics Launch $1.8B-Plus Cancer Collaboration Targeting Transcription Factors
Roche, Flare Therapeutics, transcription factors, cancer drugs, oncology, biotech collaboration